Arkolith/Insider Trading/ALBO/Form 4

Cooper Ronald Harold Wilfred

President and CEO, DirectorALBIREO PHARMA, INC. (ALBO) · full profile →Form 4 · filed Mar 2, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
1 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2023Tender(U)33K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2023Disposed to issuer(D)43K——0
Mar 2, 2023Disposed to issuer(D)93K——0
Mar 2, 2023Disposed to issuer(D)124K——0
Mar 2, 2023Disposed to issuer(D)124K——0
Mar 2, 2023Disposed to issuer(D)60K——0
Mar 2, 2023Disposed to issuer(D)19K——0
Mar 2, 2023Disposed to issuer(D)155K——0
Mar 2, 2023Disposed to issuer(D)219K——0
Mar 2, 2023Disposed to issuer(D)132K——0
Mar 2, 2023Disposed to issuer(D)124K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-014778) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML